Scrip
Santhera's idebenone fails in a Phase III trial in Friedreich's ataxia
20 May 2009
Katie McQue
Please Login to read the full article.
20 May 2009
Katie McQue
Santhera Pharmaceuticals' lead candidate, Catena (idebenone) has failed to meet the primary endpoint of a Phase III trial in Friedreich's ataxia.
The company's share price plummeted by 40% upon the news, closing at CHF30.00 on the Swiss Stock Exchange on May 19th.
The trial, named...
Please Login to read the full article.
RELATED CONTENT
SCIENCE
- Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
- Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
